Company Name | Kringle Pharma, Inc. |
---|---|
Established | December 21, 2001 |
Capital | 300 million JPY |
Main Banks | Mizuho Bank, Ltd., The Bank of Tokyo-Mitsubishi UFJ, Ltd. |
Major Stockholders | Nippon Zenyaku Kogyo Co., Ltd. Keio Innovation Initiative, Inc. DBJ Capital Co., Ltd. |
Company Mission | We will contribute to our society and global health by research, development and commercialization of innovative medicines for patients suffering from incurable diseases. |
Main Project | Research & development of HGF (pharmaceuticals for regenerative medicine) |
Kringle Pharma, Inc. was established as a pharmaceutical biotechnology venture company originating from Osaka
University in December 2001 with the goal of early development of new cancer therapies utilizing NK4. It was
2005 that Kringle Pharma, Inc. initiated the clinical development of recombinant human HGF, Hepatocyte growth
factor. Professors Nakamura and Matsumoto, who discovered HGF and NK4, became deeply engaged in the
establishment of Kringle Pharma, Inc. Professor. Matsumoto is the Chief Scientific Officer for the company, from
October 2002
to November 2013.
Kunio Iwatani, Chairman of Kringle Pharma, Inc., was previously engaged in the expansion of business for the
International Division of Takeda Chemical Ind. Ltd. for nineteen years. After holding the positions of President
and CEO of Hokuriku Seiyaku Co. Ltd. and Director of Abbott Japan Co. Ltd. successively, he filled the position
as President and CEO from March 1, 2003 to December 16, 2016.
Kiichi Adachi, President and CEO of Kringle Pharma, Inc., was previously Postdoctoral Research Associate at
Purdue University before joining Paradigm Genetics, Inc. in NC, USA. He came back to Japan to join Biotechnology
Center of Mitsui Global Strategic Studies Institute as Chief Strategist. He joined Kringle Pharma, Inc. in April
2004 and served as Director of R&D, and subsequently Director of Business Development before being appointed to
his present position in December 16, 2016.
207 Saito Bio Incubator 7-7-15 Saitoasagi, Ibaraki, OSAKA 567-0085, JAPAN
When using public transportation
Osaka Monorail Saito Line (International Culture Park City Monorail Line)
Get off at Saito Nishi Station,
about 8 minutes on foot
The time required: About 17 minutes from Senri-Chuo Station